Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Net Cash Flow (2017 - 2026)

Denali Therapeutics has reported Net Cash Flow over the past 9 years, most recently at $114.4 million for Q4 2025.

  • Quarterly Net Cash Flow rose 35.62% to $114.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.9 million through Dec 2025, down 33.35% year-over-year, with the annual reading at $31.9 million for FY2025, 33.35% down from the prior year.
  • Net Cash Flow was $114.4 million for Q4 2025 at Denali Therapeutics, up from -$50.2 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $114.4 million in Q4 2025 and troughed at -$188.5 million in Q1 2022.
  • The 5-year median for Net Cash Flow is -$3.4 million (2023), against an average of -$15.0 million.
  • Year-over-year, Net Cash Flow surged 503.37% in 2024 and then plummeted 414.87% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$101.1 million in 2021, then soared by 198.37% to $99.4 million in 2022, then plummeted by 121.03% to -$20.9 million in 2023, then surged by 503.37% to $84.3 million in 2024, then skyrocketed by 35.62% to $114.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Net Cash Flow are $114.4 million (Q4 2025), -$50.2 million (Q3 2025), and $84.3 million (Q2 2025).